Home > Insider Trading > Filing (0001104659-22-000566)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175151	Cytosorbents Corp	CTSO	Surgical & Medical Instruments & Apparatus (3841)	980373793

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1442786	P. Phillip Chan	C/O Cytosorbents Corporation 7 Deer Park Drive, Suite K Monmouth Junction NJ 08852	Chief Executive Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-12-29	100	$4.04	753,543	No	4	P	Direct
Common Stock	Acquisiton	2021-12-29	9,438	$4.05	762,981	No	4	P	Direct
Common Stock	Acquisiton	2021-12-30	5,462	$4.05	768,443	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted on December 9, 2021 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
Includes the following restricted stock units ("RSUs") that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015.
Includes the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of the Issuer's common stock upon vesting: (a) 48,000 RSUs granted on April 12, 2021 and unvested on the date hereof, and (b) 20,000 RSUs granted on February 28, 2020 and unvested on the date hereof, and
Includes 484,443 shares of the Issuer's common stock owned by the reporting person, inclusive of the 15,000 shares of the Issuer's common stock reported on this Form 4.